阿奇霉素联合匹多莫徳治疗小儿支原体肺炎的疗效与安全性分析

Analysis of the efficacy and safety of azithromycin combined with pidotimod in the treatment of pediatric mycoplasma pneumonia

目的观察并探讨阿奇霉素联合匹多莫徳治疗小儿支原体肺炎的疗效与安全性。方法 74例小儿支原体肺炎患儿,根据治疗方法的不同分为实验组和对照组,各37例。实验组患儿应用阿奇霉素联合匹多莫徳进行治疗,对照组患儿应用阿奇霉素序贯疗法进行治疗。观察并比较两组患儿的临床疗效、不良反应发生情况。结果实验组患儿治疗总有效率为94.59%(35/37),明显高于对照组的78.38%(29/37),差异有统计学意义(P<0.05)。实验组患儿不良反应发生率为5.41%(2/37),明显低于对照组的21.62%(8/37),差异有统计学意义(P<0.05)。结论阿奇霉素联合匹多莫徳治疗小儿支原体肺炎,疗效确切,安全性好,值得推广。

Objective To observe the efficacy and safety of azithromycin combined with pidotimod in the treatment of pediatric mycoplasma pneumonia.Methods A total of 74 children with mycoplasma pneumonia were divided by different treatment methods into experimental group and control group,with 37 cases in each group.The experimental group was treated with azithromycin combined with pidotimod,and the control group was treated with azithromycin sequential therapy.Observation and comparison were made on clinical efficacy and occurrence of adverse reactions between two groups.Results The experimental group had obviously higher total treatment effective rate as 94.59%（35/37） than 78.38%（29/37） in the control group,and the difference was statistically significant（P0.05）.The experimental group had obviously lower incidence of adverse reactions as 5.41%（2/37） than 21.62%（8/37） in the control group,and the difference was statistically significant（P0.05）.Conclusion Combination of azithromycin and pidotimod provides affirmative efficacy in treating pediatric mycoplasma pneumonia with high safety,and it is worthy of promotion.